Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China

BACKGROUND: Sintilimab combined with IBI305 treatment regimen had potential clinical benefits than sorafenib in the first‐line treatment of patients with unresectable hepatic cell carcinoma (HCC). However, whether sintilimab plus IBI305 has economic benefits in China remains unclear. METHODS: From t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhe, Ye, Zhuo‐miao, Tang, Yu‐kai, Deng, Dong‐feng, Zhou, Qin, Fang, Man, Zhang, Ying‐ying, Li, Xiang‐ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417160/
https://www.ncbi.nlm.nih.gov/pubmed/37434398
http://dx.doi.org/10.1002/cam4.5724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417160/
https://www.ncbi.nlm.nih.gov/pubmed/37434398
http://dx.doi.org/10.1002/cam4.5724

Ejemplares similares